Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-lactoglobulin (BLG) is the major whey protein in cow, sheep, and many other mammalian milks, though absent in human milk[3]. It is a small lipocalin protein (~18.4 kDa) capable of binding a variety of small hydrophobic molecules, including vitamins (A and D), fatty acids, cholesterol, and aromatic compounds, likely playing a role in their transport within milk[1][2][3][4]. BLG can bind iron through siderophores and may assist immune cells by transporting micronutrients, potentially influencing immune tolerance[3]. Beyond its nutritional roles, BLG is a well-recognized milk allergen in humans, significant in pediatric allergy and food safety[3]. It is not a recognized therapeutic target such as an enzyme, receptor, transporter, or transcription factor, and it currently lacks interacting drugs or well-defined mechanisms of action in therapy[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactoglobulin (BLG).